Diego Muñoz Moreno, Gilberto Pérez López, Luis Antonio Álvarez-Sala Walther, José Antonio Rueda Camino, Javier Martín Vallejo, Olga González Albarrán
{"title":"Clinical Profile and Management of Patients with Newly Diagnosed Type 2 Diabetes Mellitus in Hospital Setting.","authors":"Diego Muñoz Moreno, Gilberto Pérez López, Luis Antonio Álvarez-Sala Walther, José Antonio Rueda Camino, Javier Martín Vallejo, Olga González Albarrán","doi":"10.1177/11795514251323831","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>New-onset type 2 diabetes mellitus (T2DM) is a common clinical scenario in the hospital settings. However, data on the baseline characteristics of these patients at diagnosis in Spain remain limited.</p><p><strong>Objectives: </strong>This study aims to describe the characteristics of 165 patients admitted to a Spanish tertiary hospital with new-onset T2DM. We analysed the use of different treatment regimens at discharge and metabolic control during follow-up.</p><p><strong>Methods: </strong>A retrospective, single-centre cohort study was conducted at General University Gregorio Marañón Hospital, between January 2018 and April 2021.</p><p><strong>Results: </strong>A total of 165 patients participated, with a mean age of 56.4 years, 62.4% of whom were men. Diabetes-related complications were observed in 24.8% of patients at diagnosis. Combined antidiabetic treatment was required in 87% of cases. The mean baseline HbA1c was 10.8%, which decreased by 4.9% after 8 months of follow-up.</p><p><strong>Conclusion: </strong>The clinical heterogeneity and severity of hyperglycaemia in this cohort presented management challenges, in contrast to outpatient settings. Monotherapy was rarely used, with higher adoption of SGLT-2 inhibitors and GLP-1 receptor agonists compared to other studies. Additional research is needed to refine treatment strategies and optimize care for patients with newly diagnosed T2DM.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"18 ","pages":"11795514251323831"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898092/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Endocrinology and Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795514251323831","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: New-onset type 2 diabetes mellitus (T2DM) is a common clinical scenario in the hospital settings. However, data on the baseline characteristics of these patients at diagnosis in Spain remain limited.
Objectives: This study aims to describe the characteristics of 165 patients admitted to a Spanish tertiary hospital with new-onset T2DM. We analysed the use of different treatment regimens at discharge and metabolic control during follow-up.
Methods: A retrospective, single-centre cohort study was conducted at General University Gregorio Marañón Hospital, between January 2018 and April 2021.
Results: A total of 165 patients participated, with a mean age of 56.4 years, 62.4% of whom were men. Diabetes-related complications were observed in 24.8% of patients at diagnosis. Combined antidiabetic treatment was required in 87% of cases. The mean baseline HbA1c was 10.8%, which decreased by 4.9% after 8 months of follow-up.
Conclusion: The clinical heterogeneity and severity of hyperglycaemia in this cohort presented management challenges, in contrast to outpatient settings. Monotherapy was rarely used, with higher adoption of SGLT-2 inhibitors and GLP-1 receptor agonists compared to other studies. Additional research is needed to refine treatment strategies and optimize care for patients with newly diagnosed T2DM.